Applied Therapeutics, Inc. (APLT)
Largest Insider Buys in Sector
APLT Stock Price History Chart
APLT Stock Performance
About Applied Therapeutics, Inc.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III …
Insider Activity of Applied Therapeutics, Inc.
Over the last 12 months, insiders at Applied Therapeutics, Inc. have bought $0 and sold $9.36M worth of Applied Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Applied Therapeutics, Inc. have bought $820,285 and sold $8.73M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 30,000 shares for transaction amount of $65,367 was made by Kanter Stacy J. (director) on 2023‑12‑01.
List of Insider Buy and Sell Transactions, Applied Therapeutics, Inc.
| 2024-08-22 | Sale | Chief Medical Officer | 22,681 0.0206% | $5.83 | $132,230 | +38.84% | ||
| 2024-08-22 | Sale | Chief Financial Officer | 13,530 0.0123% | $5.83 | $78,880 | +38.84% | ||
| 2024-08-14 | Sale | President and CEO | 119,591 0.1056% | $5.93 | $709,175 | 0.00% | ||
| 2024-08-13 | Sale | President and CEO | 357,423 0.3288% | $6.18 | $2.21M | 0.00% | ||
| 2024-08-12 | Sale | President and CEO | 300,000 0.267% | $5.98 | $1.79M | +32.08% | ||
| 2024-06-06 | Sale | President and CEO | 61,795 0.0519% | $4.32 | $266,954 | +30.89% | ||
| 2024-06-06 | Sale | Chief Medical Officer | 22,003 0.0185% | $4.32 | $95,053 | +30.89% | ||
| 2024-06-06 | Sale | Chief Financial Officer | 16,980 0.0143% | $4.32 | $73,354 | +30.89% | ||
| 2024-06-05 | Sale | 10 percent owner | 150,000 0.1261% | $4.24 | $636,000 | +33.14% | ||
| 2024-06-04 | Sale | 10 percent owner | 150,000 0.131% | $4.21 | $631,500 | +39.67% | ||
| 2024-03-14 | Sale | President and CEO | 318,573 0.2652% | $5.39 | $1.72M | -4.63% | ||
| 2024-03-14 | Sale | Chief Medical Officer | 110,804 0.0922% | $5.39 | $597,234 | -4.63% | ||
| 2024-03-14 | Sale | Chief Commercial Officer | 48,871 0.0407% | $5.39 | $263,415 | -4.63% | ||
| 2024-03-14 | Sale | Chief Financial Officer | 28,727 0.0239% | $5.39 | $154,839 | -4.63% | ||
| 2023-12-01 | director | 30,000 0.0358% | $2.18 | $65,367 | +114.11% | |||
| 2023-11-30 | Sale | President and CEO | 3,968 0.0048% | $1.97 | $7,817 | +147.60% | ||
| 2023-11-30 | Sale | Chief Medical Officer | 1,583 0.0019% | $1.97 | $3,119 | +147.60% | ||
| 2023-11-30 | Sale | Chief Commercial Officer | 965 0.0012% | $1.97 | $1,901 | +147.60% | ||
| 2023-11-03 | Sale | 10 percent owner | 143,450 0.2215% | $2.31 | $331,370 | +100.00% | ||
| 2023-11-02 | Sale | 10 percent owner | 103,808 0.1662% | $2.32 | $240,835 | +104.76% |
Insider Historical Profitability
| ALEXANDRIA REAL ESTATE EQUITIES, INC. | 10 percent owner | 5855077 5.032% | $0.85 | 2 | 6 | +18.45% |
| Shendelman Shoshana | President and CEO | 4690839 4.0315% | $0.85 | 6 | 15 | +32.1% |
| Perfetti Riccardo | Chief Medical Officer | 986853 0.8481% | $0.85 | 1 | 59 | <0.0001% |
| MARCUS JOEL S | director | 365360 0.314% | $0.85 | 2 | 3 | +10.6% |
| Kanter Stacy J. | director | 63000 0.0541% | $0.85 | 3 | 0 | <0.0001% |
Institutional Investor Ownership
| Franklin Templeton Investments | $71.84M | 9.24 | 10.56M | +50.53% | +$24.12M | 0.02 | |
| Vr Adviser Llc | $61.71M | 7.94 | 9.07M | +45.2% | +$19.21M | 3 | |
| Perceptive Advisors | $54.43M | 7.01 | 8.01M | +96.19% | +$26.69M | 0.04 | |
| Janus Henderson | $43.56M | 5.61 | 6.41M | +198.57% | +$28.97M | 0.02 | |
| Tupelo Capital Management LLC | $37.91M | 4.88 | 5.57M | +1.83% | +$679,999.99 | 0.93 |